KRAS mutations, which are less common in colitis-associated CRC, can influence the efficacy of anti-EGFR therapies, while BRAF V600E mutations, typically linked to poor prognosis, are uncommon in this context. This evidence concerns the gene KRAS and colorectal carcinoma.